本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable insights to accelerate drug discovery and development SAN ANTONIO, Dec. 18, 2024 /PRNewswire/ -- Frost & Sullivan researched the bioinformatics-based drug discovery and development industry, and based on its analysis results, today recognized DNAnexus, provider of the leading enterprise platform for precision health data, with the 2024 Global Enabling Technology Leadership Award in the "bioinformatics-based drug discovery and development industry" category. DNAnexus' cloud-based platform was awarded for its ability to integrate and synchronize clinical, multi-omics, and real-world data, making it accessible, actionable, and secure while unlocking insights that can improve patient lives. The Frost & Sullivan Global Enabling Technology Award recognizes companies that have developed a pioneering technology that enhances current products and enables the development of new products and applications. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. Today, DNAnexus has more than 45,000 registered users across 48 countries and actively manages more than 105 petabytes of complex clinical genomic, proteomic, and other multi-omic datasets on behalf of a growing network of collaborators. Its comprehensive enterprise platform leverages advanced AI / ML analysis frameworks and meets the most rigorous industry standards for data quality, security, privacy, and regulatory compliance. Frost and Sullivan found the DNAnexus platform offers substantial economic benefits to customers, including a 39% return on investment and a payback period of less than six months. It also significantly reduces operating costs by automating workflows, minimizing compliance risks, and providing continuous, cloud-based updates. "DNAnexus' cloud-based platform eliminates the need to purchase or maintain hardware, and it includes convenient access to a variety of prebuilt tools and workflows," said Surbhi Gupta, Industry Principal, Frost & Sullivan. "The company's trusted research environment concept alleviates data privacy concerns posed by leading healthcare and pharmaceutical organizations. These highly secure and controlled environments allow approved researchers to access, store, and analyze sensitive data remotely." About Frost & SullivanFor six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. About DNAnexusDNAnexus, the enterprise platform for precision health data, is on a mission to accelerate the development, approval, and delivery of personalized treatments. Building on more than 15 years of bioinformatics innovation and genomics expertise, DNAnexus powers a connected data ecosystem trusted by the world's precision health leaders. This flexible ecosystem makes omics and real-world data accessible, actionable, and secure while unlocking insights that improve patient lives. For more information, visit www.dnanexus.com or follow @DNAnexus on social media. Contact: Lindsey WhitakerE: Lindsey.Whitaker@frost.com
Company Names Jacqueline Purcell as Chief Financial Officer and Claire Southey as Chief Product Development Officer NEW YORK, Dec. 18, 2024 /PRNewswire/ -- Rokt, the leading ecommerce technology company using machine learning and AI to make the shopping experience more relevant to each customer, today announced the appointment of two new leaders to its C suite. The company has named Jacqueline Purcell as Chief Financial Officer (CFO) and Claire Southey as Chief Product Development Officer, effective immediately. Purcell is an accomplished senior executive with extensive corporate finance, operational and legal experience who has worked with Rokt in a consultant capacity as interim COO since 2022. Southey is an experienced technology leader and Google and Amazon veteran who has served as SVP of Engineering in Rokt's Sydney office since May 2024. "Jacqui Purcell and Claire Southey are talented, strategic leaders and their previous experience at Rokt has prepared them exceptionally well to take on their respective new roles," said Bruce Buchanan, CEO of Rokt. "These extremely accomplished leaders both hold multiple advanced degrees and have built strong records of success at every stage of their careers. Their contributions will be invaluable to Rokt as we continue to execute our growth strategy on the path toward an IPO." Purcell's extensive experience spans complex financial transactions, relationship building, and managing and motivating large teams. She previously served as a member of the Investment Team at TDM Growth Partners, a global investment firm that partners with culture-first management teams to help scale companies. It was through this position that she originally began working with Rokt, later stepping into the interim COO role in 2022. Her earlier experience includes serving as CFO of technology solutions providers Deputy and Culture Amp and as Executive Director in Morgan Stanley's New York M&A team. She holds a Juris Doctor, with Honors, from the University of Sydney and an MBA from Stanford University. "Having worked closely with Bruce and the Rokt executive team for the past two years, I've been so impressed with their business acumen, leadership and customer-centric vision," said Purcell. "They are proven leaders and executors and it's clear from Rokt's stellar growth that they've built a strong and dynamic team environment. This company is at an exciting stage and I could not be more pleased to join the team full-time to help contribute to its continued financial success." Southey is a seasoned technology executive, data scientist and leader of high-performing software- and data-engineering teams, as well as an attorney. Prior to joining Rokt, she was Head of Customer Engineering at Google, where she oversaw engineering support for technical advancements in some of the world's largest machine learning workloads. Prior to that, Southey was Global Technical Lead at Amazon Web Services (AWS). Earlier in her career, she led technology development for companies in Sydney and London. Southey holds both an MBA and a Masters in IT Management from Charles Sturt University, a Masters in Data Science from James Cook University, and a Juris Doctor from RMIT University. "Working with the talented engineering team at Rokt has been a highly rewarding career experience," said Southey. "I'm honored to step into the Chief Product Development Officer role and excited to continue elevating our product and helping strengthen our leadership position in global ecommerce." About Rokt Rokt is the global leader in ecommerce, enabling companies to unlock value by making each transaction relevant at the moment that matters most, when customers are buying. Rokt's AI-powered relevance platform, built over the last 12 years, and scaled network power billions of transactions annually for the world's leading companies, including Live Nation, Macy's, AMC Theatres, PayPal, Uber, Hulu, Staples, Albertsons, HelloFresh and more. Headquartered in New York City, the company operates in 15 countries across North America, Europe and the Asia-Pacific region. To learn more, visit Rokt.com. Media Contact Sarah Fisher, VP Communicationssarah.fisher@rokt.com Logo - https://mma.prnasia.com/media2/2353909/Rokt_Logo.jpg?p=medium600
In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg, subcutaneous (SQ), once every four weeks plus semaglutide, 30 nmol/kg, SQ, once daily), demonstrated superior weight loss compared to semaglutide monotherapy (30 nmol/kg, SQ, once daily), showing an average total body weight reduction of 36.2% compared to 23.1%, a 56.7% greater reduction in body weight compared to semaglutide monotherapy. Human equivalent dose of ASC47 low dose 1 (3 mg/kg, SQ, once every four weeks) in mice is estimated to be approximately 20 mg based on the body surface area conversion. Interim data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via SQ injection, demonstrated a good tolerability profile up to 90 mg. The Australian SAD study is still ongoing with higher doses of ASC47. ASC47 low dose combinations with semaglutide restored the body composition of obese mice to the level of healthy non-obese mice. At the end of treatment, the percentage of total muscle mass over the total body weight of obese mice treated with ASC47 low dose combination treatments (68.8%) was similar to healthy non-obese mice (66.0%), indicating healthy weight loss. Semaglutide monotherapy was unable to restore body composition to healthy levels. ASC47 low dose combination treatments were well tolerated in obese mice and exhibited a statistically significant reduction in levels of liver enzymes such as alanine aminotransferase (ALT) compared to vehicle treatment in obese mice. HONG KONG, Dec. 18, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging efficacy results from its study in diet-induced obese (DIO) mice combining ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity, with semaglutide. ASC47 is an adipose-targeted, once-monthly subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Interim data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) showed that ASC47, via SQ injection, demonstrated a half-life of 21 days. Further, ASC47 demonstrated a good tolerability profile up to 90 mg with no serious adverse events (SAEs) and no discontinuations due to adverse events (AEs). The majority of AEs were mild (grade 1). There were no gastrointestinal or cardiac AEs reported, as well as no abnormal liver enzymes reported (Link). The Australian SAD study is still ongoing with higher doses of ASC47. In previous preclinical studies, ASC47 regular dose (45 mg/kg, SQ, once every two weeks) monotherapy demonstrated total body weight reduction of 24.6%, similar to semaglutide monotherapy (23.1%, 30 nmol/kg, SQ, once daily). ASC47 regular dose increased total muscle mass by 5.8%, compared to a decline in total muscle mass of 9.3 % for semaglutide (Link). Detailed Preclinical Data of ASC47 Low Dose Combinations The objective of the head-to-head ASC47 low dose combination DIO mouse study was to compare ASC47 low doses (3 mg/kg or 9 mg/kg) and low frequency (SQ, once every four weeks) combined with semaglutide (30 nmol/kg, SQ, once daily) against semaglutide monotherapy (30 nmol/kg, SQ, once daily). ASC47 low dose combination 1 (ASC47, 3 mg/kg, SQ, once every four weeks plus semaglutide, 30 nmol/kg, SQ, once daily) treatment was superior to semaglutide monotherapy (30 nmol/kg, SQ, once daily), showing an average total body weight reduction of 36.2% compared to 23.1%, achieving 56.7% more relative weight loss compared to semaglutide monotherapy (Table 1). Table 1. ASC47 low dose combination treatments demonstrated superior weight loss to semaglutide monotherapy Group Dosing Total body weight change from baseline Total muscle mass/total body weight Cumulative caloric intake (kCal) Healthy non-obese mice Vehicle +8.53 % 66.0 % 308 Obese mice Vehicle +8.53 % 46.6 % 378 Obese mice treated with ASC47 low dose 1 ASC47, 3 mg/kg, SQ, Q4W +5.54 % 48.6 % 388 Obese mice treated with ASC47 low dose 2 ASC47, 9 mg/kg, SQ, Q4W -1.55 % 52.1 % 348 Obese mice treated with semaglutide Semaglutide, 30 nmol/kg, SQ, QD -23.1 % 57.2 % 211 Obese mice treated with ASC47 low dose combination 1 ASC47, 3 mg/kg SQ, Q4W + semaglutide, 30 nmol/kg, SQ, QD -36.2% (p<0.0001 vs semaglutide monotherapy) 68.8% (p=0.0001 vs semaglutide monotherapy) 251 (p=0.0385 vs semaglutide monotherapy) Obese mice treated with ASC47 low dose combination 2 ASC47, 9 mg/kg, SQ, Q4W + semaglutide, 30 nmol/kg SQ, QD -35.9% (p<0.0001 vs semaglutidemonotherapy) 68.8% (p=0.0001 vs semaglutide monotherapy) 267 (p=0.001 vs semaglutide monotherapy) Note: Treatment duration: 28 days; Obese mice: diet-induced obese mice; SQ: subcutaneous; QD: once daily; Q4W: once every four weeks Human equivalent dose of ASC47 low dose 1 (3 mg/kg, SQ, once every four weeks) in mice is estimated to be approximately 20 mg based on the body surface area conversion. Interim data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated LDL-C showed that ASC47, via SQ injection, demonstrated a good tolerability profile up to 90 mg. The Australian SAD study is still ongoing with higher doses of ASC47. ASC47 low dose combinations with semaglutide restored the body composition of obese mice to the level of healthy non-obese mice. At the end of treatment, the percentage of total muscle mass over the total body weight of obese mice treated with ASC47 low dose combination treatments (68.8%) was similar to healthy non-obese mice (66.0%), indicating healthy weight loss. Semaglutide monotherapy was unable to restore body composition to healthy levels (Table 1). Cumulative caloric intake of obese mice with ASC47 low dose combination treatments at the end of treatment was statistically higher than that of obese mice with semaglutide monotherapy treatment (Table 1), suggesting that ASC47 has different mechanisms of action from incretin-based drugs. ASC47 low dose combination treatments were well tolerated in obese mice and exhibited a statistically significant reduction in levels of liver enzymes such as alanine aminotransferase (ALT) compared to vehicle treatment in obese mice (Table 2). Table 2. ASC47 low dose combination treatments demonstrated statistically significant ALT reduction compared to vehicle treatment in obese mice Group Dosing ALT (U/L) Healthy non-obese mice Vehicle 31.5 Obese mice Vehicle 234 Obese mice treated with ASC47 low dose 1 ASC47, 3 mg/kg, SQ, Q4W 182 Obese mice treated with ASC47 low dose 2 ASC47, 9 mg/kg, SQ, Q4W 159 Obese mice treated with semaglutide semaglutide, 30 nmol/kg, SQ, QD 32.9 (p<0.0001 vs vehicle treated obese mice; no significant changes vs healthy non-obese mice) Obese mice treated with ASC47 low dose combination 1 ASC47, 3 mg/kg SQ, Q4W + semaglutide, 30 nmol/kg, SQ, QD 54.1 (p<0.0001 vs vehicle treated obese mice; no significant changes vs healthy non-obese mice and semaglutide monotherapy treated obese mice) Obese mice treated with ASC47 low dose combination 2 ASC47, 9 mg/kg, SQ, Q4W + semaglutide, 30 nmol/kg SQ, QD 70.0 (p<0.0001 vs vehicle treated obese mice; no significant changes vs healthy non-obese mice and semaglutide monotherapy treated obese mice) Note: Treatment duration: 28 days; Obese mice: diet-induced obese mice; SQ: subcutaneous; QD: once daily; Q4W: once every four weeks Both ASC47 low doses statistically and significantly reduced fasting blood glucose, cholesterol and LDL-C compared to vehicle treated obese mice (Table 3). Table 3. ASC47 low dose treatments demonstrated statistically significant decreases in fasting blood glucose, cholesterol and LDL-C compared to vehicle treated obese mice Group Dosing Fasting blood glucose (mmoL/L) Cholesterol (mmoL/L) LDL-C (mmoL/L) Healthy non-obese mice Vehicle 7.5 3.53 0.50 Obese mice Vehicle 9.2 6.98 1.41 Obese mice treated with ASC47 low dose 1 ASC47, 3 mg/kg, SQ, Q4W 6.9 (p=0.0017 vs vehicle treated obese mice; no significant changes vs semaglutide monotherapy treated obese mice) 4.08 (p<0.0001 vs vehicle treated obese mice; no significant changes vs semaglutide monotherapy treated obese mice) 0.58 (p<0.0001 vs vehicle treated obese mice; no significant changes vs semaglutide monotherapy treated obese mice) Obese mice treated with ASC47 low dose 2 ASC47, 9 mg/kg, SQ, Q4W 5.7 (p<0.0001 vs vehicle treated obese mice; no significant changes vs semaglutide monotherapy treated obese mice) 3.32 (p<0.0001 vs vehicle treated obese mice; no significant changes vs semaglutide monotherapy treated obese mice) 0.44 (p<0.0001 vs vehicle treated obese mice; no significant changes vs semaglutide monotherapy treated obese mice) Obese mice treated with semaglutide Semaglutide, 30 nmol/kg, SQ, QD 6.4 (p=0.0001 vs vehicle treated obese mice) 3.90 (p<0.0001 vs vehicle treated obese mice) 0.61 (p<0.0001 vs vehicle treated obese mice) Note: Treatment duration: 28 days; Obese mice: diet-induced obese mice; SQ: subcutaneous; QD: once daily; Q4W: once every four weeks In obese mice, ASC47 low dose combination treatments reduced statistically and significantly more fasting blood glucose, cholesterol and LDL-C than semaglutide monotherapy treated obese mice (Table 4). Table 4. ASC47 low dose combination treatments demonstrated superior fasting blood glucose, cholesterol and LDL-C reductions compared to semaglutide monotherapy Group Dosing Fasting blood glucose (mmoL/L) Cholesterol (mmoL/L) LDL-C (mmoL/L) Obese mice treated with ASC47 low dose combination 1 ASC47, 3 mg/kg SQ, Q4W + semaglutide, 30 nmol/kg, SQ, QD 5.3 (p=0.0024 vs semaglutide monotherapy) 2.65 (p=0.0003 vs semaglutide monotherapy) 0.35 (p=0.0045 vs semaglutide monotherapy) Obese mice treated with ASC47 low dose combination 2 ASC47, 9 mg/kg, SQ, Q4W + semaglutide, 30 nmol/kg SQ, QD 4.7 (p<0.0001 vs semaglutide monotherapy) 2.57 (p=0.0002 vs semaglutide monotherapy) 0.36 (p=0.0055 vs semaglutide monotherapy) Obese mice treated with semaglutide Semaglutide, 30 nmol/kg, SQ, QD 6.4 3.90 0.61 Note: Treatment duration: 28 days; Obese mice: diet-induced obese mice; SQ: subcutaneous; QD: once daily; Q4W: once every four weeks "We are excited by these data showing that adipose-targeted ASC47 low dose combination treatments achieved 56.7% more relative weight loss compared to semaglutide monotherapy. Importantly, in the preclinical study, adipose-targeted ASC47 low dose combination treatments produced healthy weight loss, increasing our confidence that ASC47-based combination therapies may clinically improve weight loss and muscle preservation compared to incretin-based drugs alone," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, " Unlike liver enzyme elevations observed with an apelin receptor (APJ) agonist, low doses of ASC47 in combination with an incretin-based drug showed statistically significant reductions in liver enzymes. We are advancing development of ASC47 as both a monotherapy at regular doses and a combination therapy at low doses for the treatment of obesity and other metabolic diseases." Ascletis Obesity Portfolio ASC47 is an adipose-targeted, once-monthly subcutaneously injected THRβ selective small molecule agonist. Interim data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. ASC47 is currently in the clinical trials of patients with obesity in Australia, with topline data of Phase IIa study expected in the second quarter of 2025. In addition to ASC47, Ascletis is also developing ASC30, a GLP-1 receptor (GLP-1R) biased small molecule that can be dosed once daily orally or once monthly subcutaneously. Both ASC30 once-daily oral tablet (NCT06680440) and ASC30 once-monthly SQ injection (NCT06679959) are currently in Phase Ib clinical trials in the U.S. for the treatment of obesity, with topline data expected in the first quarter of 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis has rapidly advanced its pipeline, focusing on two therapeutic areas with unmet medical needs from a global perspective: metabolic diseases and viral diseases. Ascletis has multiple clinical stage drug candidates in its R&D pipeline. For more information, please visit www.ascletis.com. Contact:Peter VozzoICR Healthcare443-231-0505 (U.S.)Peter.vozzo@icrhealthcare.com Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)pr@ascletis.com ir@ascletis.com
LONDON, Dec. 18, 2024 /PRNewswire/ -- By 2030, the manufacturing industry is projected to generate 4.4 zettabytes of data worldwide, according to forecasts by global technology intelligence firm ABI Research. This massive data stream, originating from IoT sensors, CNC systems, ERP platforms, automated identification readers, and MES systems, represents a transformative opportunity for enterprises to sustain competitiveness, drive innovation, and enable AI-driven solutions. However, many enterprises and digitalization providers lack the expertise to fully leverage this data, resulting in inefficiencies and revenue losses amounting to hundreds of millions of dollars annually. "Generating a lot of data is one thing – being able to analyze and prepare this data for Large Language Models and AI algorithm training is another," states Leo Gergs, Principal Analyst at ABI Research. "Data fabrics hold immense promise in transforming enterprise operations through seamless integration, enhanced governance, and automated data management. To unlock their full potential, it's imperative to address a spectrum of challenges spanning technology, governance, operations, and organizational readiness." Integrating legacy systems, on-premises platforms, and cloud-native solutions into a cohesive data fabric is a major hurdle. Vendors like Databricks, IBM, and NetApp are developing platforms that unify these environments, enabling real-time data processing and seamless compatibility. Gergs explains, "The ability to bridge diverse systems is critical to unlocking the true value of data fabrics. Enterprises manage sensitive and regulated data that require strict compliance frameworks." Solutions like Informatica's Intelligent Data Management Cloud, Palantir Foundry, Cloudera's Data Platform, and AWS Industrial Data Fabric enable enterprises to enforce governance with automated lineage tracking, access control, and encryption. Data fabrics must ensure trust and compliance, particularly in sectors like healthcare, manufacturing, and government. Traditional methods like manual ETL and siloed systems hinder scalability. Vendors such as Qlik, Denodo, Databricks, and Microsoft Fabric are addressing these bottlenecks by automating workflows, enhancing real-time analytics, and streamlining operations. According to Gergs, "Enterprises are looking to data fabrics for faster, smarter, and more efficient data handling. Balancing customization for unique enterprise needs with scalable solutions is essential. But in all of this, the right balance between customization and standardization is critical for widespread adoption and long-term success." To overcome these challenges, vendors must go beyond delivering technology, providing comprehensive integration support, education, and ongoing collaboration with enterprises. "The key to success is not just selling a product but enabling a partnership. Vendors must walk together with enterprises, guiding them through integration, building workforce capabilities, and ensuring long-term value. A proactive and supportive approach will transform obstacles into opportunities," Gergs advises. These findings are from ABI Research's Overcoming Challenges in Bringing Data Fabrics to Industrial Enterprises report. This report is part of the company's Hybrid Cloud & 5G Markets research service, which includes research, data, and ABI Insights. About ABI Research ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers. ABI Research是一家全球性的技术情报公司，拥有得天独厚的优势，充当终端市场公司和技术解决方案提供商之间的桥梁，通过提供独家研究和专业性指导，推动成功的技术实施和提供经证明可吸引和留住客户的战略，无缝连接这两大主体。 For more information about ABI Research's services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com. Contact Info: Global Deborah Petrara Tel: +1.516.624.2558 pr@abiresearch.com
Dusit Princess Chiang Mai reopens with a fresh new look, enhanced guest experiences, and participation in the 'Get Ready for Northern Tourism Campaign. dusitD2 Fagu, Shimla, the first Dusit-branded hotel in India, makes its debut in the Himalayas. BANGKOK, THAILAND - Media OutReach Newswire - 18 December 2024 - Dusit Hotels and Resorts, under Dusit International, one of Thailand's leading hotel and property development companies, is welcoming the peak travel season with the opening of two exciting properties: Dusit Princess Chiang Mai in Thailand and dusitD2 Fagu, Shimla, the first Dusit-branded hotel in India. Dusit Princess Chiang Mai showcases a vibrant new look and enhanced guest experiences, perfectly capturing the timeless charm and cultural essence of northern Thailand. Located in the heart of Chiang Mai on Chang Klan Road, just steps from iconic landmarks such as Wat Chedi Luang and the renowned Night Bazaar, the upper-midscale Dusit Princess Chiang Mai provides an ideal base for exploring this vibrant northern city. Following a comprehensive three-year transformation, the well-known property reopened earlier this month with a fresh new look and elevated guest experiences that highlight the timeless charm of northern Thailand. Key enhancements include redesigned guestrooms, inspired by local traditions and crafted for comfort and functionality, along with upgraded facilities tailored to meet the needs of modern travellers. These include state-of-the-art meeting spaces, a serene pool area, a well-equipped gym, and a revitalised lobby that reflects the elegance of Lanna culture. The hotel's dining offerings have also been elevated, with Jasmine Restaurant delivering a culinary journey through Chinese and Cantonese cuisine, and the newly introduced Casa Verde serving a vibrant mix of international and Asian favourites alongside Mexican-inspired delights. To support the local community, Dusit Princess Chiang Mai is participating in the Tourism Authority of Thailand's "Nuea... Phrom Tiew" (Get Ready for Northern Tourism) campaign. Designed to revitalise tourism following recent flooding in the region, the initiative offers special discounts for domestic travellers who register via the official campaign website. Outside Thailand, Dusit Hotels and Resorts has officially re-entered India with the opening of dusitD2 Fagu, Shimla, which welcomed its first guests on 15 December 2024. Set amidst the majestic Himalayas, just 20 kilometres from Shimla—the capital and largest city of Himachal Pradesh—dusitD2 Fagu offers a serene escape for luxury travellers, health enthusiasts, and adventure seekers alike. The upscale retreat features 80 elegantly designed guestrooms, ranging from 38 to 86 square metres, all with breathtaking views of the surrounding valleys and mountains. Guests can enjoy a variety of facilities, including the region's largest temperature-controlled swimming pool and the signature Namm Spa, which offers authentic Thai massage therapies and wellness treatments. The hotel is also set to become a premier venue for events, with versatile function spaces including the region's largest banquet hall, an expansive terrace lawn, and the only outdoor amphitheatre in the area. Dining options include Dusit Gourmet, which serves a variety of international dishes for all-day dining, and SOI, specialising in authentic Thai and Pan-Asian cuisine. Shimla Airport is just an 80-minute drive away, while Chandigarh Airport, with daily flights from major cities such as Delhi, Mumbai, and Bangalore, is reachable in four-and-a-half hours. The hotel is also only 18 kilometres from Kalka Railway Station, seven kilometres from Kufri, and 133 kilometres from Chandigarh. Guests at dusitD2 Fagu can easily explore nearby attractions such as Mahasu Peak, which offers breathtaking views of the Badrinath and Kedarnath ranges, and the UNESCO-listed Shimla-Kalka Toy Train, a narrow-gauge railway that traverses a stunning mountainous route from Kalka to Shimla. "We are thrilled to expand Dusit's footprint into India with the opening of dusitD2 Fagu, Shimla, our very first hotel in this vibrant and diverse country," said Gilles Cretallaz, Chief Operating Officer, Dusit International. "India represents an important market for Dusit, and we have high expectations for its development potential, with four additional properties already in the pipeline and more expected to follow soon. At the same time, we remain committed to enhancing our presence in beloved destinations such as Chiang Mai, where we are proud to unveil the new-look Dusit Princess Chiang Mai. These openings reflect our dedication to delivering unique, localised experiences that celebrate the culture and charm of each destination, while consistently providing the Thai-inspired gracious hospitality that defines Dusit. As we grow, we look forward to creating enduring value for our guests, communities, and partners alike." Dusit's portfolio currently includes 301 properties operating across 19 countries, including 57 properties under Dusit Hotels and Resorts and 244 luxury villas under Elite Havens, the leading provider of luxury villa rentals in Asia. For more information about the new hotels and opening offers, please visit: dusit.com/dusitd2-fagu and dusit.com/dusitprincess-chiangmai. Hashtag: #dusitinternationalThe issuer is solely responsible for the content of this announcement.About Dusit InternationalEstablished in 1948, Dusit International or Dusit Thani Public Company Limited (DUSIT) is a leading hospitality group listed on the Stock Exchange of Thailand. Its operations comprise five distinct yet complementary business units: Dusit Hotels and Resorts, Dusit Hospitality Education, Dusit Foods, Dusit Estate, and Hospitality-Related Services. Dusit International's diversified investments in real estate development, hospitality-related services, and the food sector are part of its long-term strategy for sustainable growth, which focuses on three key areas: balance, expansion and diversification. For more information, please visit dusit-international.com About Dusit Hotels and Resorts Dusit Hotels and Resorts is the hotel arm of Dusit International, one of Thailand's leading hotel and property development companies. With a heartfelt belief and commitment to introducing Thai-inspired gracious hospitality to the world, Dusit Hotels and Resorts offers guests a uniquely special stay in high-style surroundings and a personalised approach to service. The group's portfolio of hotels, resorts and luxury villas includes more than 300 properties operating under a total of eight brands (Devarana – Dusit Retreats, Dusit Thani, Dusit Suites, Dusit Collection, dusitD2, Dusit Princess, ASAI Hotels, and Elite Havens) across 18 countries worldwide. For more information, please visit dusit.com
HONG KONG SAR - Media OutReach Newswire - 18 December 2024 - Blue Cross (Asia-Pacific) Insurance Limited ("Blue Cross") and Public Bank (Hong Kong) Limited ("Public Bank") today announced and signed a bancassurance agreement. Customers of Public Bank can now purchase two selected insurance products "TravelSafe Plus" and "HomeSafe Protection Insurance" offered by Blue Cross, through the bank's branch network and website. Mr. Chong Yam Kiang, Executive Director & Chief Executive of Public Bank (left) and Ms. Bonnie Tse, Chief Executive Officer of Blue Cross (right) announce the bancassurance partnership. Rooted in Hong Kong for decades, Blue Cross and Public Bank share a common vision of providing innovative, high-quality solutions and services to customers. Blue Cross has rich experience in general insurance and has a leading digital platform to provide fast, safe and reliable insurance service experience. Public Bank has a huge customer base. This bancassurance partnership combines the huge resources, industry expertise and service network of both parties, and will surely exert synergy to provide customers with more timely, convenient and comprehensive living protection. Key features of selected insurance products: TravelSafe Plus Worldwide medical expenses benefit and personal accident benefit up to HK$1,200,000 each; coverage for trip cancellation, interruption and travel delay, and 24-hour worldwide emergency aid services. HomeSafe Protection Insurance A host of combined protection benefits that cover household content up to HK$1,200,000, personal belongings and third-party liability. Disclaimers: This press release is for distribution in Hong Kong only. The distribution of this press release is not and shall not be construed as an offer to sell or a solicitation to buy or a provision of any insurance product outside Hong Kong. Blue Cross (Asia-Pacific) Insurance Limited is a subsidiary of AIA Group Limited. It is not affiliated with or related in any way to Blue Cross and Blue Shield Association or any of its affiliates or licensees. Hashtag: #BlueCrossThe issuer is solely responsible for the content of this announcement.Blue Cross (Asia-Pacific) Insurance LimitedBlue Cross (Asia-Pacific) Insurance Limited ("Blue Cross") is a subsidiary of AIA Group Limited. With over 50 years of operational experience in the insurance industry, Blue Cross provides a comprehensive range of products and services including medical, travel and general insurance, which cater to the needs of both individual and corporate customers. Blue Cross distributes its products through various channels, including AIA agency force, online platform, direct sales, BEA network, insurance agents and brokers, as well as travel agencies. In 2023, Blue Cross is assigned financial strength rating of A+ (stable outlook) and issuer credit rating of A+ (stable outlook) by S&P Global Ratings. Public Bank (Hong Kong) LimitedPublic Bank (Hong Kong) Limited ("Public Bank (Hong Kong)" or the "Bank") is a commercial bank registered under the Banking Ordinance of Hong Kong and under the supervision of the Hong Kong Monetary Authority ("HKMA"). For more details, please visit www.publicbank.com.hk.
A12 藝術空間
D-Link
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
